{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:36:25Z","timestamp":1760315785821,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jjcc.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T16:53:57Z","timestamp":1565628837000},"page":"203-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia"],"prefix":"10.1016","volume":"75","author":[{"given":"Rie","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2019.07.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106250","article-title":"Major molecular response achievement in CML patients can be predicted by BCR-ABL1\/ABL1 or BCR-ABL1\/GUS ratio at an earlier time point of follow-up than currently recommended","volume":"9","author":"Huet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3960\/jslrt.54.197","volume":"54","author":"Inokuchi","year":"2014","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14740331003742935","article-title":"Pleural\/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development","volume":"9","author":"Breccia","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-2-46","article-title":"The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib","volume":"2","author":"Masiello","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.13R13CP","article-title":"Therapeutic potential of vasopressin-receptor antagonists in heart failure","volume":"124","author":"Izumi","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12872-017-0598-y","article-title":"Effects of tolvaptan in patients with acute heart failure: a systematic review and meta-analysis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0045","unstructured":"U.S. Department of Health and Human Services NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. November 27, 2017."},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2019.07.008_bib0050","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s10557-011-6348-y","article-title":"Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study","volume":"25","author":"Fukunami","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0055","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0060","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clinthera.2012.01.009","article-title":"Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"34","author":"Abbott","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0065","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0070","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0075","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0080","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0090","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","article-title":"The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro","volume":"127","author":"Blake","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0100","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0110","article-title":"Effects and safety of oral tolvaptan in patients with congestive heart failure: a systematic review and network meta-analysis","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jjcc.2018.10.003","article-title":"Update of acute and long-term tolvaptan therapy","volume":"73","author":"Imamura","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.07.008_bib0120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jjcc.2018.02.006","article-title":"Comparison of two dosing methods for immediate administration of tolvaptan in acute decompensated heart failure","volume":"72","author":"Oguri","year":"2018","journal-title":"J Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:02:29Z","timestamp":1760274149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508719302242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0914508719302242"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.07.008","relation":{},"ISSN":["0914-5087"],"issn-type":[{"type":"print","value":"0914-5087"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}